What was studied?
A randomized, double-blind phase 2 trial enrolled 190 participants with biopsy-confirmed MASH and F2 or F3 fibrosis. The main endpoint was MASH resolution without worsening fibrosis after 52 weeks; missing biopsy data required prespecified handling.
What did the researchers report?
The reported active-treatment groups more often met the primary histologic endpoint than placebo. Fibrosis-related improvement was also investigated. Gastrointestinal events were the most common adverse events described in the abstract.
What are the limits?
A phase 2 biopsy endpoint does not establish long-term clinical outcomes. Missing observations and the selected fibrosis stages affect interpretation. These findings should be evaluated with later research, not converted into efficacy promises for research-supply vials.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.